Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

4.19
Delayed Data
As of Jul 31
 +0.052 / +1.26%
Today’s Change
2.62
Today|||52-Week Range
7.26
-32.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$55.8M

Company Description

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical products. Its products are concentrated in major therapeutic areas, respiratory disease, allergy, and oncology. The company combines specialty pharmaceuticals and biotechnology to provide medicines for patients, physicians and healthcare organizations. It is focused on the development of preventive and therapeutic vaccine products and cancer drugs for patients with unmet medical needs. Adamis Pharmaceuticals was founded on April 1, 2009 and is headquartered in San Diego, CA.

Contact Information

Adamis Pharmaceuticals Corp.
11455 El Camino Real
San Diego California 92130
P:(858) 997-2400
Investor Relations:
(858) 412-7951

Employees

Shareholders

Mutual fund holders2.55%
Other institutional18.38%
Individual stakeholders17.45%

Top Executives

Dennis J. CarloPresident, Chief Executive Officer & Director
Karen K. DanielsVice President-Operations
Robert O. HopkinsChief Financial Officer, Secretary & VP
Thomas H. MollVice President-Research
David J. MarguglioDirector & Senior VP-Corporate Development